Galderma is set to become the world’s largest independent dermatology company following the completion of CHF 10.2 billion deal for Nestle’s Skin Health division. The acquisition, which includes the ProActiv operation in the UK, was led by a consortium comprising the EQT VIII fund, Luxvina, PSP Investments and other institutional investors.
Galderma offers a range of medical and consumer skin health solutions through three business units: Aesthetics, Prescription and Consumer Care with combined revenues of CHF 2.8 billion and some 5000 employees worldwide. Dr Flemming Ornskov assumes the CEO role with Thomas Dittrich joining as CFO. The business will continue to be headquartered in Switzerland.
It is understood that the ProActiv range will continue to be marketed direct to consumers by the London based UK team which is now led by Claire Odom.
Share